Xolair ‘add-on’ useful in uncontrolled asthma

	Tweet

Individuals with severe persistent asthma who fail to gain adequate control despite standard treatment with multiple anti-asthma drugs, may benefit from the addition of Xolair (omalizumab), a study suggests.

Xolair is a laboratory-generated monoclonal antibody that is given by injection once or twice a month. It is designed to bind to IgE, a naturally-occurring antibody, and prevent it from triggering the release of chemicals that provoke asthma and allergy attacks.

In the study, 419 patients with severe persistent asthma were randomized to Xolair or placebo for 28 weeks.

All patients were receiving high doses of inhaled corticosteroids plus so-called long-acting beta2-agonists and two thirds were receiving additional controller medications including 22% who were taking oral corticosteroids. All patients impaired lung function and a history of recent asthma attacks.

They report that Xolair was associated with a 26% reduction in the rate of clinically significant asthma exacerbations compared with placebo.

Xolair add-on also significantly reduced the rate of severe asthma attacks and emergency room visits and led to “meaningful improvement” in asthma related quality-of-life, study investigator Dr. Phillip Korenblat from Washington University School of Medicine in St. Louis told Reuters Health.

Xolair, he said, “should be considered in this group of patients with severe persistent asthma who continue to have unmet needs despite the best available therapy.”

These results will be presented next week at the 61st annual meeting of the American Academy of Allergy, Asthma & Immunology in San Antonio.

The study was sponsored by Novartis Pharma AG and Genentech, manufacturers of Xolair.

SOURCE: Allergy 2005.

RELATED STORIES:
New study: Knoxville is ‘asthma capital’   Biofeedback helps reduce steroid use by asthmatics   Acetaminophen could up asthma, wheezing risk   Breastfeeding protects against asthma, allergy   Asthma rate and costs from traffic-related air pollution are much higher than once believed   Inhaled budesonide safe for infants with asthma   Workplace asthma under scrutiny   Patient factors predict asthma therapy response   Under-tongue immunotherapy cuts asthma in kids   Flu shot doesn’t prevent kids’ asthma flare-ups   Vitamin D helps fend off flu, asthma attacks: study   Parents’ anti-asthma efforts often off-target

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]